BioCryst Pharmaceuticals, Inc.
BCRX
$8.73
$0.789.81%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 503.49M | 450.71M | 412.58M | 382.24M | 355.40M |
| Total Other Revenue | -- | 3.89M | 6.41M | 7.47M | 8.95M |
| Total Revenue | 503.49M | 450.71M | 412.58M | 382.24M | 355.40M |
| Cost of Revenue | 181.08M | 187.00M | 198.54M | 202.25M | 215.09M |
| Gross Profit | 322.41M | 263.72M | 214.04M | 179.99M | 140.31M |
| SG&A Expenses | 289.24M | 266.26M | 249.82M | 235.38M | 225.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 470.31M | 453.26M | 448.36M | 437.63M | 440.25M |
| Operating Income | 33.17M | -2.54M | -35.78M | -55.39M | -84.85M |
| Income Before Tax | -51.18M | -86.95M | -124.13M | -146.50M | -208.58M |
| Income Tax Expenses | 2.29M | 1.93M | -308.00K | -564.00K | 4.00K |
| Earnings from Continuing Operations | -53.47 | -88.88 | -123.82 | -145.93 | -208.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.47M | -88.88M | -123.82M | -145.93M | -208.59M |
| EBIT | 33.17M | -2.54M | -35.78M | -55.39M | -84.85M |
| EBITDA | 36.21M | 469.00K | -33.21M | -52.71M | -82.09M |
| EPS Basic | -0.26 | -0.43 | -0.61 | -0.73 | -1.07 |
| Normalized Basic EPS | -0.15 | -0.26 | -0.37 | -0.44 | -0.56 |
| EPS Diluted | -0.26 | -0.43 | -0.61 | -0.73 | -1.07 |
| Normalized Diluted EPS | -0.15 | -0.26 | -0.37 | -0.44 | -0.56 |
| Average Basic Shares Outstanding | 829.59M | 826.78M | 820.80M | 803.54M | 786.24M |
| Average Diluted Shares Outstanding | 835.97M | 826.78M | 820.80M | 803.54M | 786.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |